Back to Journals » OncoTargets and Therapy » Volume 6

Combined upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 predicts unfavorable prognosis in human nasopharyngeal carcinoma

Authors Yang R, Xu Y, Li P, Zhang X, Wang J, Gu D, Wang Y

Received 23 June 2013

Accepted for publication 10 July 2013

Published 20 August 2013 Volume 2013:6 Pages 1139—1146

DOI https://doi.org/10.2147/OTT.S50389

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Download Article [PDF] 

Rui Yang,1 Yu Xu,2 Peizhong Li,2 Xin Zhang,2 Junying Wang,2 Dongsheng Gu,2 Yao Wang3

1State Key Laboratory of Cancer Biology, Cell Engineering Research Center and Department of Cell Biology, Department of Clinical Nursing, School of Nursing, The Fourth Military Medical University, Xi'an, People’s Republic of China; 2Department of Otorhinolaryngology, Huai'an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu, People’s Republic of China; 3Pharmaceutical Preparation Section, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, People’s Republic of China

Background: The upregulation of matrix metalloproteinase-1 (MMP-1) has been demonstrated to be correlated with lymph node metastasis of nasopharyngeal carcinoma (NPC), while the activation of protease-activated receptor-1 (PAR-1) mediates proliferation and invasion of NPC cells. The present study investigated the clinical significance of the coexpression of MMP-1 and PAR-1 in NPC patients in determining the prognosis.
Methods: Immunohistochemistry was performed to detect the expression of MMP-1 and PAR-1 in tumor tissue samples from 266 NPC patients.
Results: Overexpression of MMP-1 and PAR-1 proteins were, respectively, detected in 190 (71.43%) and 182 (68.42%) of the 266 NPC patients. In addition, the combined MMP-1 and PAR-1 expression was significantly associated with advanced T-stage (P = 0.01), advanced clinical stage (P = 0.002), positive recurrence (P = 0.01), and metastatic status (P = 0.01) of NPC. Moreover, the overall survival in NPC patients with MMP-1 and PAR-1 dual overexpression was significantly shorter than in those with dual low expression (P < 0.001). Furthermore, the multivariate analyses indicated that the combined MMP-1 and PAR-1 overexpression was an independent prognostic factor for overall survival (P = 0.001) in NPC patients, but the upregulation of MMP-1 and PAR-1 alone was, in each case, not an independent prognostic factor for this disease.
Conclusion: Our data provide convincing evidence, for the first time, that the activation of the MMP-1 and PAR-1 axis may be involved in the tumorigenesis and progression of NPC. The upregulation of MMP-1 in combination with PAR-1 overexpression is an unfavorable prognostic marker for NPC and might offer the possibility of future therapeutic targets.

Keywords: MMP-1, PAR-1, nasopharyngeal carcinoma, coexpression, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]